Dyne Therapeutics' Recent DMD Study Data Further Validates Force Platform, Morgan Stanley Says

MT Newswires Live12-10

Dyne Therapeutics' (DYN) recent Duchenne muscular dystrophy, or DMD, study data further validates the company's Force platform, Dyne's drug delivery technology, Morgan Stanley said in a Tuesday note.

On Monday, Dyne Therapeutics said its phase 1/2 trial of zeleciment rostudirsen in an expanded group of Duchenne muscular dystrophy patients met its primary endpoint.

"The positive results for z-rostudirsen increase the potential for accelerated approval in DMD and enhance its competitive profile," the Morgan Stanley analysts said.

Morgan Stanley further increased its probability for success in DMD to 70% from 55% previously and peak market share in US to 42% from 25%, and in EU to 25% from 20%.

The firm raised price target on Dyne Therapeutics to $50 from $46, along with an overweight rating.

Price: 19.24, Change: -2.96, Percent Change: -13.32

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590281203?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-10 00:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590281203","market":"hk","top_or_hot":-1,"title":"Dyne Therapeutics' Recent DMD Study Data Further Validates Force Platform, Morgan Stanley Says","media":"MT Newswires Live","content":"<html><body><p> Dyne <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (DYN) recent Duchenne muscular dystrophy, or DMD, study data further validates the company's Force platform, Dyne's drug delivery technology, Morgan Stanley said in a Tuesday note.</p><p>On Monday, Dyne Therapeutics said its phase 1/2 trial of zeleciment rostudirsen in an expanded group of Duchenne muscular dystrophy patients met its primary endpoint.</p><p>\"The positive results for z-rostudirsen increase the potential for accelerated approval in DMD and enhance its competitive profile,\" the Morgan Stanley analysts said.</p><p>Morgan Stanley further increased its probability for success in DMD to 70% from 55% previously and peak market share in US to 42% from 25%, and in EU to 25% from 20%.</p><p>The firm raised price target on Dyne Therapeutics to $50 from $46, along with an overweight rating.</p><p>Price: 19.24, Change: -2.96, Percent Change: -13.32</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dyne Therapeutics' Recent DMD Study Data Further Validates Force Platform, Morgan Stanley Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDyne Therapeutics' Recent DMD Study Data Further Validates Force Platform, Morgan Stanley Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-10 00:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Dyne <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (DYN) recent Duchenne muscular dystrophy, or DMD, study data further validates the company's Force platform, Dyne's drug delivery technology, Morgan Stanley said in a Tuesday note.</p><p>On Monday, Dyne Therapeutics said its phase 1/2 trial of zeleciment rostudirsen in an expanded group of Duchenne muscular dystrophy patients met its primary endpoint.</p><p>\"The positive results for z-rostudirsen increase the potential for accelerated approval in DMD and enhance its competitive profile,\" the Morgan Stanley analysts said.</p><p>Morgan Stanley further increased its probability for success in DMD to 70% from 55% previously and peak market share in US to 42% from 25%, and in EU to 25% from 20%.</p><p>The firm raised price target on Dyne Therapeutics to $50 from $46, along with an overweight rating.</p><p>Price: 19.24, Change: -2.96, Percent Change: -13.32</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1791710400.SGD","symbol_name":"Fidelity Global Demographics A-ACC-SGD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2590281203","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590281203","pubTimestamp":1765297769,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Dyne Therapeutics'  recent Duchenne muscular dystrophy, or DMD, study data further validates the company's Force platform, Dyne's drug delivery technology, Morgan Stanley said in a Tuesday note.On Monday, Dyne Therapeutics said its phase 1/2 trial of zeleciment rostudirsen in an expanded group of Duchenne muscular dystrophy patients met its primary endpoint.\"The positive results for z-rostudirsen increase the potential for accelerated approval in DMD and enhance its competitive profile,\" the Morgan Stanley analysts said.Morgan Stanley further increased its probability for success in DMD to 70% from 55% previously and peak market share in US to 42% from 25%, and in EU to 25% from 20%.The firm raised price target on Dyne Therapeutics to $50 from $46, along with an overweight rating.Price: 19.24, Change: -2.96, Percent Change: -13.32","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","BK4581":"高盛持仓","LU0106831901.USD":"贝莱德世界金融基金A2","LU0882574139.USD":"富达环球消费行业基金A ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","BK4139":"生物科技","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","BK4127":"投资银行业与经纪业","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","BK4516":"特朗普概念","DYN":"戴纳基","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4505":"高瓴资本持仓","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","BK4504":"桥水持仓","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","BK4588":"碎股","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0557290698.USD":"施罗德环球可持续增长基金","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1548497426.USD":"安联环球人工智能AT Acc","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU0971096721.USD":"富达环球金融服务 A","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1"},"translate_title":"摩根士丹利表示，Dyne Therapeutics最近的DMD研究数据进一步验证了Force平台","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DYN":1.5},"content_text":"Dyne Therapeutics' (DYN) recent Duchenne muscular dystrophy, or DMD, study data further validates the company's Force platform, Dyne's drug delivery technology, Morgan Stanley said in a Tuesday note.On Monday, Dyne Therapeutics said its phase 1/2 trial of zeleciment rostudirsen in an expanded group of Duchenne muscular dystrophy patients met its primary endpoint.\"The positive results for z-rostudirsen increase the potential for accelerated approval in DMD and enhance its competitive profile,\" the Morgan Stanley analysts said.Morgan Stanley further increased its probability for success in DMD to 70% from 55% previously and peak market share in US to 42% from 25%, and in EU to 25% from 20%.The firm raised price target on Dyne Therapeutics to $50 from $46, along with an overweight rating.Price: 19.24, Change: -2.96, Percent Change: -13.32","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590281203","isCrawlerRequest":true}